【意大利首例弥漫性大b细胞淋巴瘤患者行轴细胞二线治疗：创新与传统】

Q3 Medicine

Recenti progressi in medicina Pub Date : 2025-02-01 DOI:10.1701/4450.44450

Stefania Bramanti, Davide Chizzoniti, Daniele Mannina

{"title":"【意大利首例弥漫性大b细胞淋巴瘤患者行轴细胞二线治疗：创新与传统】","authors":"Stefania Bramanti, Davide Chizzoniti, Daniele Mannina","doi":"10.1701/4450.44450","DOIUrl":null,"url":null,"abstract":"CAR-T cell therapy has revolutionized the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) within 12 months, replacing the use of high-dose chemotherapy with autologous stem cell reinfusion. Primary chemoresistance remains one of the most unfavorable prognostic scenarios for patients with DLBCL, despite the progress made with the introduction of anti-CD20 monoclonal antibodies in first-line treatment. Early identification of prognostic factors associated with clinical presentation represents an integrated approach that ensures rapid access to autologous anti-CD19 CAR-T therapy in selected cases that may benefit from treatment according to current standard indications.","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 2","pages":"e24-e27"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The first Italian patient affected by diffuse large B-cell lymphoma treated with axi-cel in the second line: innovation and tradition.]\",\"authors\":\"Stefania Bramanti, Davide Chizzoniti, Daniele Mannina\",\"doi\":\"10.1701/4450.44450\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"CAR-T cell therapy has revolutionized the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) within 12 months, replacing the use of high-dose chemotherapy with autologous stem cell reinfusion. Primary chemoresistance remains one of the most unfavorable prognostic scenarios for patients with DLBCL, despite the progress made with the introduction of anti-CD20 monoclonal antibodies in first-line treatment. Early identification of prognostic factors associated with clinical presentation represents an integrated approach that ensures rapid access to autologous anti-CD19 CAR-T therapy in selected cases that may benefit from treatment according to current standard indications.\",\"PeriodicalId\":20887,\"journal\":{\"name\":\"Recenti progressi in medicina\",\"volume\":\"116 2\",\"pages\":\"e24-e27\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recenti progressi in medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1701/4450.44450\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4450.44450","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

CAR-T细胞疗法在12个月内彻底改变了难治性或复发性弥漫性大b细胞淋巴瘤（DLBCL）的治疗，用自体干细胞再输注取代了高剂量化疗的使用。尽管在一线治疗中引入抗cd20单克隆抗体取得了进展，但原发性化疗耐药仍然是DLBCL患者最不利的预后情况之一。早期识别与临床表现相关的预后因素是一种综合方法，可确保在根据当前标准适应症进行治疗的特定病例中快速获得自体抗cd19 CAR-T治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[The first Italian patient affected by diffuse large B-cell lymphoma treated with axi-cel in the second line: innovation and tradition.]

CAR-T cell therapy has revolutionized the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) within 12 months, replacing the use of high-dose chemotherapy with autologous stem cell reinfusion. Primary chemoresistance remains one of the most unfavorable prognostic scenarios for patients with DLBCL, despite the progress made with the introduction of anti-CD20 monoclonal antibodies in first-line treatment. Early identification of prognostic factors associated with clinical presentation represents an integrated approach that ensures rapid access to autologous anti-CD19 CAR-T therapy in selected cases that may benefit from treatment according to current standard indications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Recenti progressi in medicina Medicine-Medicine (all)

CiteScore

0.90

自引率

0.00%

发文量

143

期刊介绍： Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.